Document:

Series E Preferred Stock & Warrant Purchase Agreement

 Exhibit 10.2 
  
  
  
  
  
 XCYTE THERAPIES, INC. 
  
 SERIES E PREFERRED STOCK 
  
 AND WARRANT PURCHASE AGREEMENT 
  
  
 November 13, 2001 

 TABLE OF CONTENTS 
  

	 	 	 	  	 	  	Page

	 1. PURCHASE AND SALE OF STOCK
	  	1
				
	 	 	 1.1
	  	 AUTHORIZATION, SALE AND ISSUANCE OF
SHARES
	  	1
	 	 	 1.2
	  	 CLOSING
	  	1
	 	 	 1.3
	  	 DELIVERY
	  	2
	 	 	 1.4
	  	 ADDITIONAL CLOSINGS
	  	2
		
	 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	  	2
				
	 	 	 2.1
	  	 ORGANIZATION, GOOD STANDING AND
QUALIFICATION
	  	2
	 	 	 2.2
	  	 AUTHORIZATION
	  	3
	 	 	 2.3
	  	 CAPITALIZATION
	  	3
	 	 	 2.4
	  	 SUBSIDIARIES
	  	4
	 	 	 2.5
	  	 GOVERNMENTAL CONSENTS
	  	4
	 	 	 2.6
	  	 PROPRIETARY INFORMATION AGREEMENT
	  	4
	 	 	 2.7
	  	 PATENTS AND TRADEMARKS
	  	4
	 	 	 2.8
	  	 FINANCIAL STATEMENTS.
	  	5
	 	 	 2.9
	  	 CHANGES.
	  	5
	 	 	 2.10
	  	     LIABILITIES.
	  	6
	 	 	 2.11
	  	     LITIGATION
	  	6
	 	 	 2.12
	  	     COMPLIANCE WITH OTHER
INSTRUMENTS
	  	7
	 	 	 2.13
	  	     OFFERING.
	  	7
	 	 	 2.14
	  	     AGREEMENTS; ACTION
	  	7
	 	 	 2.15
	  	     LABOR AGREEMENTS AND
ACTIONS
	  	8
	 	 	 2.16
	  	     TAX RETURNS, PAYMENTS AND
ELECTIONS
	  	8
	 	 	 2.17
	  	     TITLE TO PROPERTY AND
ASSETS
	  	8
	 	 	 2.18
	  	     REGISTRATION RIGHTS
	  	9
	 	 	 2.19
	  	     EMPLOYEE BENEFIT PLANS
	  	9
	 	 	 2.20
	  	     OBLIGATIONS OF MANAGEMENT.
	  	9
	 	 	 2.21
	  	     ENVIRONMENTAL AND SAFETY
LAWS.
	  	9
	 	 	 2.22
	  	     DISCLOSURE
	  	9
	 	 	 2.23
	  	     SECTION 83(B) ELECTIONS.
	  	9
	 	 	 2.24
	  	     REAL PROPERTY HOLDING
CORPORATION.
	  	9
	 	 	 2.25
	  	     INSURANCE.
	  	9
	 	 	 2.26
	  	     INVESTMENT COMPANY ACT.
	  	9
		
	 3. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR
	  	9
				
	 	 	 3.1
	  	 AUTHORIZATION
	  	10
	 	 	 3.2
	  	 PURCHASE ENTIRELY FOR OWN ACCOUNT
	  	10
	 	 	 3.3
	  	 DISCLOSURE OF INFORMATION
	  	10
	 	 	 3.4
	  	 INVESTMENT EXPERIENCE
	  	10
	 	 	 3.5
	  	 REGULATION D.
	  	10
	 	 	 3.6
	  	 RESTRICTED SECURITIES
	  	10
	 	 	 3.7
	  	 LEGENDS
	  	11
	 	 	 3.8
	  	 REGULATION S
	  	11
		
	 4. CONDITIONS OF INVESTOR’S OBLIGATIONS AT CLOSING
	  	11
				
	 	 	 4.1
	  	 REPRESENTATIONS AND WARRANTIES
	  	11

 TABLE OF CONTENTS 
 (cont’d.) 
  

	 	 	 	  	 	  	Page

	 	 	 4.2
	  	 PERFORMANCE
	  	 11

	 	 	 4.3
	  	 CERTIFICATE
	  	 11

	 	 	 4.4
	  	 COMPLIANCE CERTIFICATE
	  	 12

	 	 	 4.5
	  	 PROCEEDINGS AND DOCUMENTS
	  	 12

	 	 	 4.6
	  	 BOARD OF DIRECTORS.
	  	 12

	 	 	 4.7
	  	 RIGHTS AGREEMENT
	  	 12

	 	 	 4.8
	  	 CO-SALE AGREEMENT
	  	 12

	 	 	 4.9
	  	 OPINION OF COMPANY COUNSEL
	  	 12

		
	 5. CONDITIONS OF THE COMPANY’S OBLIGATIONS AT CLOSING
	  	 12

				
	 	 	 5.1
	  	 REPRESENTATIONS AND WARRANTIES
	  	 12

	 	 	 5.2
	  	 LEGAL MATTERS
	  	 12

		
	 6. MISCELLANEOUS
	  	 13

				
	 	 	 6.1
	  	 SURVIVAL OF WARRANTIES
	  	 13

	 	 	 6.2
	  	 SUCCESSORS AND ASSIGNS
	  	 13

	 	 	 6.3
	  	 GOVERNING LAW
	  	 13

	 	 	 6.4
	  	 COUNTERPARTS
	  	 13

	 	 	 6.5
	  	 TITLES AND SUBTITLES
	  	 13

	 	 	 6.6
	  	 NOTICES
	  	 13

	 	 	 6.7
	  	 FINDER’S FEE
	  	 13

	 	 	 6.8
	  	 AMENDMENTS AND WAIVERS
	  	 13

	 	 	 6.9
	  	 SEVERABILITY.
	  	 14

	 	 	 6.10
	  	     EXCULPATION AMONG INVESTORS.
	  	 14

	 	 	 6.11
	  	     EXPENSES
	  	 14

  

 ii 

	 EXHIBITS

		
	 A
	  	 Schedule of Investors

	 B
	  	 Form of Amended and Restated Certificate of Incorporation

	 C
	  	 Schedule of Exceptions

	 D
	  	 Form of Proprietary Information Agreement

	 E
	  	 Form of Amended and Restated Investor Rights Agreement

	 F
	  	 Form of Amended and Restated Right of First Refusal and Co-Sale Agreement

	 G
	  	 Form of Opinion of Counsel to the Company

	 H
	  	 Additional Representations and Warranties of Foreign Investors

 XCYTE THERAPIES, INC. 
  
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT 
  
 THIS SERIES E PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is made as of the
13th day of November, 2001, by and between Xcyte Therapies, Inc., a Delaware corporation, located at 1124 Columbia
Street, Suite 130, Seattle, WA 98104 (the “Company”), and the investors listed on Exhibit A hereto, each of which is herein referred to as an “Investor.” 
  
 WHEREAS, the Company desires to issue and sell up to 4,750,362 shares of
Series E Preferred Stock and to issue warrants to purchase 2,586,308 shares of Common Stock to the Investors; and 
  
 WHEREAS, the Investors desire to purchase such shares and warrants from the Company on the terms and subject to the conditions of this Agreement.

  
 NOW THEREFORE, the parties hereby agree as follows:

  
 1. Purchase and Sale of Stock. 
  
 1.1 Authorization, Sale and Issuance of Shares 
  
 (a) The Company has authorized the sale and issuance of up to 6,500,000
shares of Series E Preferred Stock (the “Series E Shares”) and the issuance of warrants to purchase 2,586,308 shares of Common Stock (the “Warrants” and together with the Series E Shares the
“Shares”). The Series E Shares have the rights, preferences, privileges and restrictions as set forth in the Company’s Restated Certificate of Incorporation in the form satisfactory to the Investors, a copy of which is attached
hereto as Exhibit B. The Common Stock issuable upon conversion of the Series E Shares is referred to hereinafter as the “Conversion Shares” and the Common Stock issuable upon exercise of the Warrants is referred to
hereinafter as the “Warrant Shares.” 
  
 (b)
Subject to the terms and conditions of this Agreement, the Company shall sell and issue to each Investor, and each Investor agrees, severally and not jointly, to purchase from the Company, that number of (i) Shares of Series E Preferred Stock at a
purchase price of $2.78 per share and (ii) Warrants at a cash purchase price of $0.001 per share of Common Stock set forth opposite each Investor’s name on Exhibit A attached hereto. Each Investor understands that the Shares and the
Warrants cannot be purchased separately and must be purchased in the proportion allocated on Exhibit A. 
  
 1.2 Closing. The purchase and sale of the Shares shall take place at the offices of Venture Law Group, 4750 Carillon Point, Kirkland, Washington,
at 10:00 a.m., on November 13, 2001, or at such other time and place as the Company and Investors may agree (which time 

 
and place are designated as the “Closing”). The date of such Closing is hereinafter referred to as the “Closing Date.”

  
 1.3 Delivery. At the Closing, the Company shall deliver
to each Investor a certificate representing the Shares which such Investor is purchasing against delivery to the Company by such Investor of a check, wire transfer of immediately available funds payable to the Company’s order or cancellation of
indebtedness (or any combination thereof) in the aggregate amount of the purchase price therefor. 
  
 1.4 Additional Closings. If the full number of Series E Shares of the Company is not sold at the Closing, the Company shall have the right, at any
time within one hundred twenty (120) days of the Closing Date (the “Subsequent Closing Date”), to sell the remaining authorized but unissued shares of Series E Shares and Warrants to purchase Common Stock to one or more additional
purchasers as determined by the Company, or to any Investor hereunder who wishes to acquire additional shares of Series E Shares and Warrants to purchase Common Stock at the price and on the terms set forth herein, provided that any such additional
purchaser shall be required to execute counterpart signature pages to this Agreement, the Investors’ Rights Agreement and the Co-Sale Agreement (each as defined in Section 2.2), and such additional purchasers will, upon delivery to the Company
of such signature pages and the purchase price, become parties to, and be bound by, such agreements, each to the same extent as if they had been Investors at the initial Closing. Immediately after each additional closing, Exhibit A to this
Agreement will be amended to list the additional purchasers purchasing shares of Series E Shares and Warrants to purchase Common Stock hereunder at each such additional closing. Any additional purchaser so acquiring shares of Series E Shares and
Warrants to purchase Common Stock shall be considered an “Investor” for the purposes of the Financing Documents (as defined below), and any Series E Shares so acquired by such additional purchaser shall be considered “Series
E Shares” and any Warrants to purchase Common Stock so acquired by such additional purchaser shall be considered “Warrants,” and together with the Series E Shares the “Shares”) for purposes of this
Agreement and all other agreements contemplated hereby. 
  
 2.
Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that, except as set forth on the Schedule of Exceptions attached hereto as Exhibit C, which exceptions shall be deemed to be
representations and warranties as if made hereunder: 
  
 2.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its
business as now conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business or
properties. As of the Closing, the Certificate shall be in the form attached hereto as Exhibit B and the Bylaws of the Company shall be in the form provided to counsel for the Investors prior to the Closing. 
  

 2 

 2.2 Authorization. 
  
 (a) The Company has all requisite corporate power and authority to execute and deliver, and to consummate the transactions
contemplated by this Agreement, the Amended and Restated Investor Rights Agreement attached as Exhibit E (“Rights Agreement”) and the Amended and Restated Right of First Refusal and Co-Sale Agreement attached as Exhibit
F (the “Co-Sale Agreement” with the Agreement and Rights Agreement, the “Financing Documents”). All corporate action on the part of the Company, its officers, directors and stockholders necessary for the
execution and delivery of, and the consummation of the transactions contemplated by the Financing Documents, the performance of all obligations of the Company under the Financing Documents and the authorization, sale, issuance (or reservation for
issuance) and delivery of the Shares being sold hereunder and the Conversion Shares and Warrant Shares has been taken or will be taken prior to the Closing. The Financing Documents, upon execution and delivery by the Company and assuming the due and
proper execution and delivery by the other parties, constitute valid and binding obligations of the Company enforceable in accordance with their respective terms, except as such enforcement may be limited by bankruptcy, insolvency, moratorium and
other laws of general application affecting the enforcement of creditors’ rights. 
  
 (b) The Shares, when issued in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable and will be free of any liens or encumbrances known to, or caused or created by,
the Company; provided, however, that the Shares may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein, as may be required by changes in such laws and as contemplated by the Financing
Documents. Upon conversion of the Series E Shares into the Conversion Shares and Warrants into Warrant Shares in conformity with the Certificate, such Conversion Shares and Warrant Shares will be duly authorized, validly issued, fully paid and
nonassessable, and will be free of any liens or encumbrances caused or created by the Company; provided, however, that the Conversion Shares and Warrant Shares may be subject to restrictions on transfer under state and/or federal
securities laws as set forth herein, as may be required by changes in such law and as contemplated by the Financing Documents. 
  
 (c) Except as set forth herein or in the Financing Documents, no entity has any right of first refusal or any preemptive rights in connection with the
issuance of the Shares, the Warrant Shares, the Conversion Shares or any future issuances of securities by the Company. 
  
 2.3 Capitalization. 
  
 (a) Immediately prior to the Closing, the authorized capital of the Company shall consist of: (i) 60,000,000 shares of Common Stock, and (ii), 35,409,976
shares of Preferred Stock (the “Preferred Stock”), of which 7,300,080 have been designated Series A Preferred Stock, 4,097,580 have been designated Series B Preferred Stock, 7,212,316 have been designated Series C Preferred Stock,
10,300,000 have been designated Series D Preferred Stock and 6,500,000 have been designated Series E Preferred Stock. Immediately prior to the Closing, 

  

 3 

 
7,434,567 shares of Common Stock, warrants to purchase 496,948 shares of Common Stock, 6,860,512 shares of Series A Preferred Stock, warrants to purchase
439,568 shares of Series A Preferred Stock, 3,903,080 shares of Series B Preferred Stock, warrants to purchase 194,500 shares of Series B Preferred Stock, 7,185,630 shares of Series C Preferred Stock, and warrants to purchase 26,686 shares of Series
C Preferred Stock, 10,109,825 shares of Series D Preferred Stock, warrants to purchase 103,741 shares of Series D Preferred Stock and no shares of Series E Preferred Stock will be outstanding. 
  
 (b) Except as set forth in this Agreement and the exhibits thereto, there
are no outstanding options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the Company of any shares of its capital stock except that the Company has reserved (i) the Shares for
issuance at each Closing, (ii) the Common Stock issuable upon conversion of the Preferred Stock, (iii) 5,600,000 shares of Common Stock reserved for issuance pursuant to stock option plans adopted by the Company of which 1,786,049 options have been
granted and remain outstanding, with 3,041,532 shares remaining for grant. 
  
 2.4 Subsidiaries. The Company does not presently own or control, directly or indirectly, any interest in any other corporation, association, or other business entity. 
  
 2.5 Governmental Consents. 
  
 (a) No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by the Financing Documents.

  
 (b) No consent, approval, waiver or other action by any
person under any contract, agreement, indenture, lease, instrument or other document to which the Company is a party or bound is required or necessary for the execution, delivery and performance of, or the consummation of the transactions
contemplated by, any of the Financing Documents by the Company. 
  
 2.6 Proprietary Information Agreement. Each former and present employee, consultant and officer of the Company has executed and each future employee, consultant and officer will execute, a Proprietary Information Agreement in the
form attached hereto as Exhibit D and no exceptions have been taken by any such employee, consultant or officer to the terms of such agreement. The Company, after reasonable investigation, is not aware that any of its employees, officers or
consultants are in violation thereof, and the Company will use its best efforts to prevent any such violation. 
  
 2.7 Patents and Trademarks. The Company has sufficient title and ownership of all patents, trademarks, service marks, trade names, copyrights,
trade secrets, information, proprietary rights and processes necessary for its business as now conducted and as proposed to be conducted without any conflict with or infringement of the rights of others. There are no 

  

 4 

 
outstanding options, licenses, or agreements of any kind relating to the foregoing, nor is the Company bound by or a party to any options, licenses or
agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any other person or entity. The Company has not received any
communications alleging that the Company has violated or, by conducting its business as proposed, would violate any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person
or entity. The Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative
agency, that would interfere with the use of his or her best efforts to promote the interests of the Company or that would conflict with the Company’s business as proposed to be conducted. Neither the execution nor delivery of this Agreement,
nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as proposed, will, to the best of the Company’s knowledge, conflict with or result in a breach of the terms,
conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such employees is now obligated. The Company does not believe it is or will be necessary to utilize any inventions of any of its
employees (or people it currently intends to hire) made prior to their employment by the Company. 
  
 2.8 Financial Statements. The Company has delivered to each Investor (i) its unaudited balance sheet as of August 31, 2001 and unaudited statement
of income for the period from January 1, 2001 to August 31, 2001 and audited financial statements as of December 31, 2000 (collectively the “Financial Statements”). The Financial Statements, together with the notes thereto, are
complete and correct in all material respects and have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods indicated, except as disclosed therein, and present fairly the
financial condition and position of the Company as of August 31, 2001; provided, however, that the unaudited financial statements are subject to normal recurring year-end audit adjustments (which are not expected to be material), and do not contain
all footnotes required under generally accepted accounting principles. 
  
 2.9 Changes. Since August 31, 2001, there has not been: 
  
 (a) Any change in the assets, liabilities, financial condition or operations of the Company from that reflected in the Financial Statements, other than changes in the ordinary course of business, or any other event or
condition of any character, any of which individually or in the aggregate has had or is expected to have a material adverse effect on such assets, liabilities, financial condition or operations of the Company; 
  
 (b) Any resignation or termination of any key officers of the Company; and
the Company, to the best of its knowledge, does not know of the impending resignation or termination of employment of any such officer; 
  

 5 

 (c) Any material change, except in the ordinary course of business, in the contingent obligations of the
Company by way of guaranty, endorsement, indemnity, warranty or otherwise; 
  
 (d) Any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting the properties, business or prospects or financial condition of the Company; 
  
 (e) Any direct or indirect loans made by the Company to, or any material
change in, any compensation arrangement or agreement with, any stockholder, employee, officer or director of the Company, other than advances made in the ordinary course of business; 
  
 (f) Any declaration or payment of any dividend or other distribution of the assets of the Company; 
  
 (g) Any debt, obligation or liability incurred, assumed or guaranteed by the
Company, except those for immaterial amounts and for current liabilities incurred in the ordinary course of business; or any waiver by the Company of a valuable right or of a material debt owed to it; 
  
 (h) Any sale, assignment or transfer of any patents, trademarks, copyrights,
trade secrets or other intangible assets; and 
  
 (i) To the
Company’s knowledge, any change in any material agreement to which the Company is a party or by which it is bound which materially and adversely affects the business, assets, liabilities, financial condition, operations or prospects of the
Company, including compensation agreements with the Company’s employees. 
  
 2.10 Liabilities. The Company has no material liabilities and knows of no material contingent liabilities not disclosed in the Financial Statements, except current liabilities incurred in the ordinary course of
business subsequent to August 31, 2001, which have not been, either in any individual case or in the aggregate, materially adverse. 
  
 2.11 Litigation. There is no action, suit, proceeding or investigation pending or currently threatened against the Company that questions the
validity of this Agreement or the right of the Company to enter into it, or to consummate the transactions contemplated hereby, or which might result, either individually or in the aggregate, in any material adverse changes in the assets, condition,
affairs or prospects of the Company, financially or otherwise, or any change in the current equity ownership of the Company, nor is the Company aware that there is any basis for the foregoing. The foregoing includes, without limitation, actions
pending or threatened (or any basis therefor known to the Company) involving the prior employment of any of the Company’s employees, their use in connection with the Company’s business of any information or techniques allegedly proprietary
to any of their former employers, or their obligations under any agreements with prior employers. The Company is not a party or subject to the provisions of 

  

 6 

 
any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation
by the Company currently pending or which the Company intends to initiate. 
  
 2.12 Compliance with Other Instruments. The Company is not in violation or default of any provision of its Certificate or Bylaws or any provision of any mortgage, indenture, contract, agreement, instrument,
judgment, order, writ, or decree to which it is a party or by which it is bound or, to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company which would materially and adversely affect the
business, assets, liabilities, financial condition, operations or prospects of the Company. The execution, delivery and performance of this Agreement, the Rights Agreement and the Co-Sale Agreement and the consummation of the transactions
contemplated hereby and thereby will not result in any such material violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order,
writ, decree or contract or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company. 
  
 2.13 Offering. Subject in part to the accuracy of the Investors’ representations set forth in Section 3 hereof, the offer, sale and issuance
of the Shares as contemplated by this Agreement and the issuance of the Conversion Shares or Warrant Shares upon the conversion of such Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the
“Securities Act”), and the registration, qualification or compliance requirements of any applicable blue sky or other state securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action
that would cause the loss of any such exemption. 
  
 2.14
Agreements; Action. 
  
 (a) There are no agreements,
understandings or proposed transactions between the Company and any of its officers, directors, affiliates, or any affiliate thereof. 
  
 (b) There are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound
which involve (i) obligations of, or payments to the Company in excess of $25,000, or (ii) the license of any patent, copyright, trade secret or other proprietary right to or from the Company (other than licenses arising from the purchase of
“off-the-shelf” products) or (iii) obligations of, or payments by, the Company to any officer, director, employee or family member of any such individual. 
  
 (c) The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to
any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $25,000 or in excess of $75,000 in the aggregate, (iii) made any loans or advances to any person,
other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than in the ordinary course of business. 
  

 7 

 (d) The Company is not a party to and is not bound by any contract, agreement or instrument, or subject
to any restriction under its Certificate or Bylaws, which materially adversely affects its business as now conducted and as proposed to be conducted. 
  
 (e) The Company has not engaged in the past twelve (12) months in any discussion (i) with any representative of any corporation or corporations regarding
the consolidation or merger of the Company with or into any such corporation or corporations, (ii) with any corporation, partnership, association or other business entity or any individual regarding the sale, conveyance or disposition of all or
substantially all of the assets of the Company, or (iii) regarding any other form of liquidation, dissolution or winding up of the Company. 
  
 2.15 Labor Agreements and Actions. The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any
written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the knowledge of the Company, has sought to represent any of the employees, representatives or agents of the
Company. There is no strike or other labor dispute involving the Company pending, or to the knowledge of the Company threatened, which could have a material adverse effect on the assets, properties, financial condition, operating results, or
business of the Company (as such business is presently conducted and as it is proposed to be conducted), nor is the Company aware of any labor organization activity involving its employees. To the best of its knowledge, the Company is not aware that
any officer or key employee, or that any group of key employees, intends to terminate their employment with the Company, nor does the Company have a present intention to terminate the employment of any of the foregoing. The employment of each
officer and employee of the Company is terminable at the will of the Company. 
  
 2.16 Tax Returns, Payments and Elections. The Company has filed all tax returns and reports as required by law. These returns and reports are true and correct in all material respects. The Company has paid all
taxes and other assessments due, except those contested by it in good faith which are listed in the Schedule of Exceptions, attached hereto as Exhibit C. The provision for taxes of the Company as shown in the Balance Sheet is adequate for
taxes due or accrued as of the date thereof. The Company has not elected pursuant to the Internal Revenue Code of 1986, as amended (the “Code”), to be treated as a Subchapter S corporation or a collapsible corporation pursuant to
Section 1362(a) or Section 341(f) of the Code, respectively, nor has it made any other elections pursuant to the Code (other than elections which relate solely to methods of accounting, depreciation or amortization) which would have a material
effect on the Company, its financial condition, its business as presently conducted or proposed to be conducted or any of its properties or material assets. 
  
 2.17 Title to Property and Assets. The Company owns its property and assets free and clear of all mortgages, liens, loans and encumbrances, except
such encumbrances and liens which arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in compliance
with such leases and, to the best of its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances. 
  

 8 

 2.18 Registration Rights. Except as provided in the Rights Agreement, a form of which is attached
hereto as Exhibit E, the Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity. 
  
 2.19 Employee Benefit Plans. The Company does not have any Employee Benefit Plan as defined in the Employee Retirement Income Security Act of 1974,
as amended. 
  
 2.20 Obligations of Management. Each
officer of the Company is currently devoting his or her full-time to the conduct of the business of the Company. The Company is not aware of any officer or key employee or the Company planning to work less than full-time at the Company in the
future. 
  
 2.21 Environmental and Safety Laws. To the best
of its knowledge, the Company is not in violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply
with any such existing statute, law or regulation. 
  
 2.22
Disclosure. The Company has fully provided each Investor with all the information which such Investor has requested for deciding whether to purchase the Shares and all information which the Company believes is reasonably necessary to enable
such Investor to make such decision. To the best of the Company’s knowledge, neither this Agreement, the Rights Agreement, the Co-Sale Agreement nor any other statements or certificates made or delivered in connection herewith, when taken as a
whole, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading. 
  
 2.23 Section 83(b) Elections. To the Company’s knowledge, all elections and notices permitted by Section 83(b) of the Internal Revenue Code
and analogous provisions of applicable state tax laws have been timely filed by all employees who have purchased shares of the Company’s common stock under agreements that provide for the vesting of such shares. 
  
 2.24 Real Property Holding Corporation. The Company is not a real
property holding corporation within the meaning of Internal Revenue Code Section 897(c)(2) and any regulations promulgated thereunder. 
  
 2.25 Insurance. The Company has fire and casualty insurance policies with coverage customary for companies similarly situated to the Company.

  
 2.26 Investment Company Act. The Company is not an
“investment company”, or a company “controlled” by an “investment”, within the meaning of the Investment Company Act of 1940, as amended. 
  
 3. Representations and Warranties of the Investor. Each Investor hereby severally and not jointly represents and
warrants that: 
  

 9 

 3.1 Authorization. This Agreement when executed and delivered by such Investor shall constitute a
valid and legally binding obligation, enforceable in accordance with its terms, subject to the effect of applicable bankruptcy, insolvency, reorganization, moratorium or other similar federal or state laws affecting the rights of creditors and the
effect of rules of law governing specific performance, injunctive relief or other equitable remedies. 
  
 3.2 Purchase Entirely for Own Account. This Agreement is made with each Investor in reliance upon such Investor’s representations and
warranties to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Shares to be received by such Investor, the Warrant Shares and the Conversion Shares (collectively, the
“Securities”) will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, each Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any person or entity
to sell, transfer or grant participation to such person or to any third person, with respect to any of the Securities. Each Investor represents that it has full power and authority to enter into this Agreement. 
  
 3.3 Disclosure of Information. Each Investor believes it has received
all the information it considers necessary or appropriate for deciding whether to purchase the Shares. Each Investor further represents that it has had an opportunity to ask questions, if any, and receive answers from the Company regarding the terms
and conditions of the offering of the Shares. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investors to rely thereon. 
  
 3.4 Investment Experience. Each Investor is an investor in securities
of companies in the development stage and acknowledges that it is able to fend for itself, and bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the
merits and risks of the investment in the Shares. If other than an individual, Investor also represents it has not been organized for the purpose of acquiring the Shares. 
  
 3.5 Regulation D. Each Investor is an “Accredited Investor” as that term is defined in Regulation D
promulgated under the Securities Act. 
  
 3.6 Restricted
Securities. Each Investor understands that the Shares it is purchasing (and the Conversion Shares) are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a
transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. In this connection, each Investor
represents that it is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. 
  

 10 

 3.7 Legends. It is understood that the certificates evidencing the Series E Preferred Stock (or
the Conversion Shares) and the Warrants (or the Warrant Shares) may bear one or all of the following legends: 
  
 (a) “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO
RULE 144 OF SUCH ACT. THESE SECURITIES ARE SUBJECT TO A CERTAIN VOTING PROVISION ENTERED INTO BY AND AMONG THE INVESTORS.” 
  
 (b) “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR APPLICABLE SECURITIES LAWS.
THESE SECURITIES MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OTHER THAN IN COMPLIANCE WITH REGULATION S OF THE ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE ACT AND APPLICABLE STATE SECURITIES LAWS.” 
  
 (c) Any other legends required by the laws of the State of Delaware or any other applicable blue sky or state securities laws. 
  
 3.8 Regulation S. China Development Industrial Bank Inc. hereby makes
the additional representations and warranties set forth in Exhibit H. 
  
 4. Conditions of Investor’s Obligations at Closing. The obligations of each Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, any of
which may be waived in whole or in part by such Investor with respect to himself, herself or itself unless required by state or federal law: 
  
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing
Date with the same effect as though such representations and warranties had been made on and as of the date of the Closing. 
  
 4.2 Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the Closing. 
  
 4.3 Certificate. The Certificate shall have been filed with the Secretary of State of the State of Delaware. 
  

 11 

 4.4 Compliance Certificate. The President of the Company shall deliver to counsel for the
Investors at the Closing a certificate certifying that the conditions specified in Sections 4.1, 4.2 and 4.3 have been fulfilled and stating that there shall have been no adverse change in the business, affairs, prospects, operations, properties,
assets, liabilities or condition of the Company since the date of this Agreement. 
  
 4.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and
substance to each Investor and counsel to any of the Investors, and they shall have received all such counterpart original and certified or other copies of such documents as they may reasonably request. 
  
 4.6 Board of Directors. As of the Closing, the Board of Directors will
be comprised of seven members: Ronald J. Berenson, Robert Curry, Jean Deleage, Peter Langecker, Robert Nelsen, Michael Steinmetz and Robert Williams. 
  
 4.7 Rights Agreement. The Company and the Investors shall have entered into the Rights Agreement in the form attached hereto as Exhibit E.

  
 4.8 Co-Sale Agreement. The Company, certain
stockholders and certain of the Investors shall have entered into the Co-Sale Agreement in the form attached hereto as Exhibit F. 
  
 4.9 Opinion of Company Counsel. The Investors shall have received from Venture Law Group, counsel to the Company, an opinion addressed to them,
dated the Closing Date, in the form attached hereto as Exhibit G. 
  
 5. Conditions of the Company’s Obligations at Closing. The obligations of the Company to each Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following
conditions any of which may be waived in whole or in part by the Company unless required by state or federal law: 
  
 5.1 Representations and Warranties. The representations and warranties of each Investor contained in Section 3 hereof shall be true and correct on
and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of that date; and each Investor shall have performed all obligations and conditions required to be performed or observed by he, she
or it on or prior to the Closing Date. 
  
 5.2 Legal
Matters. All material matters of a legal nature which pertain to this agreement and the transactions contemplated hereby, shall have been reasonably approved by counsel to the Company. 
  

 12 

 6. Miscellaneous. 
  
 6.1 Survival of Warranties. The warranties, representations and covenants of the Company and Investors contained in
or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company.

  
 6.2 Successors and Assigns. The terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  
 6.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Washington.

  
 6.4 Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement. 
  
 6.6 Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal deliver to the party to be notified, the refusal of delivery by such person, or five (5) days
after deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party in Exhibit A attached hereto or in the case of the Company on
the first page of this Agreement, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties. 
  
 6.7 Finder’s Fee. Each party represents that it neither is nor will be obligated for any finders’ fee or commission in connection with
this transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or
asserted liability) for which the Investor or any of its officers, partners, employees, or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the
nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
  
 6.8 Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally or in a 

  

 13 

 
particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Series E
Shares. Any amendment or waiver effected in accordance with this Section 6.8 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities are
convertible), each future holder of all such securities, and the Company; provided, however, that no condition set forth in Section 4 hereof may be waived with respect to any Investor who does not consent thereto. 
  
 6.9 Severability. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

  
 6.10 Exculpation Among Investors. Each Investor
acknowledges that it is not relying upon any person, firm or corporation, other than the Company and its officers and directors, in making its investment decision to invest in the Company. Each Investor agrees that no other Investor nor the
respective controlling persons, officers, directors, partners, agents or employees of any such other Investor shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with each Investor’s
purchase of the Shares, Conversion Shares and Warrant Shares. 
  
 6.11 Expenses. Upon the Closing of the purchase and sale of securities as contemplated by this Agreement and the exhibits thereto, the Company shall pay the fees and reasonable expenses of counsel for the Investors, which fees shall
not exceed $10,000.00. 
  
 (signature page follows)

  

 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

	XCYTE THERAPIES, INC.
		
	By:	 	/s/    RONALD J. BERENSON        
	 	 	

	 Name:
	 	Ronald Jay Berenson
	 	 	

	 	 	(print)
	 Title:
	 	President & CEO
	 	 	

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

	CDIB Biotech USA Investment, Co., Ltd.
		
	By:	 	 /s/    BING
SHEN        

	 Name:
	 	 Bing Shen

	 Title:
	 	 Chairman

	
	 Legal Address:      PO Box 3444
 Road Town
 Tortola, British Virgin
Islands
  
 Mailing Address:  CDIB Biotech, Inc.
 21 N. Skokie Highway
 Suite 104
 Lake Bluff, IL
60044
 Attn: Bing Shen, Chairman
  
 Phone Number:     (847) 283-9780

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

	DLJ CAPITAL CORP.
		
	By:	 	 /s/    ARTHUR S.
ZUCKERMAN        

	 Name:
	 	 Arthur S. Zuckerman

	 Title:
	 	 President

	
	 Address:      3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park,
CA 94025
 Attn: Robert Curry

	
	DLJ FIRST ESC L.P.
		
	By:	 	 /s/    ARTHUR S.
ZUCKERMAN        

	 Name:
	 	 Arthur S. Zuckerman

	 Title:
	 	 Attorney In Fact

	
	 Address:      3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park,
CA 94025
 Attn: Robert Curry

	
	SPROUT CAPITAL VII, L.P.
		
	By:	 	 /s/    ARTHUR S.
ZUCKERMAN        

	 Name:
	 	 Arthur S. Zuckerman

	 Title:
	 	 President

	
	 Address:      3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park,
CA 94025
 Attn: Robert Curry

	
	ARCH VENTURE FUND III, L.P.

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

	 ARCH Venture Fund III, L.P.

	 a Delaware limited partnership

	 By:    ARCH Venture Partners
L.L.C.
      a Delaware limited partnership,
            its General Partner

		
	 By:
	 	 /s/    ROBERT T.
NELSEN        

	 Name:
	 	 Robert T. Nelsen

	 Title:
	 	 Managing Director

	
	 Address:      1000 Second Avenue, Suite
3700
 Seattle, WA 98104-1053
 Attn: Bob Nelsen

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 
  

	 ALTA CALIFORNIA PARTNERS, L.P.
 By: Alta California Management Partners, L.P.

		
	By:	 	  /s/    JEAN DELEAGE

	 	 	         General Partner

	 Name:
	 	  

	
	 Address:      One Embarcadero Center, Suite
4050
 San Francisco, CA 94111
 Attn: Elaine Walker

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

	TGI FUND II, LC
	
	 By:            Tredegar Investments,
Inc.

	 Its Sale Manager

		
	By:	 	 /s/    NANCY M. TAYLOR
        

	 Name:
	 	 Nancy M. Taylor

	 Title:
	 	 Vice President

	
	 Address:      6501 Columbia Center
 701 - 5th Avenue
 Seattle, WA
98104
 Attn: Michael Beblo and Steven Johnson

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 
  
  

	 MPM ASSET MANAGEMENT
 INVESTORS 2000 B, L.L.C.

		
	 By:
	 	   /s/    MICHAEL STEINMETZ

	
	 Name: Michael Steinmetz

	 Title: Investment Manager

  

	 MPM BIOVENTURES GMBH & CO.

	 PARALLEL-BETEILIGUNGS KG

	 By:    MPM Asset Management II, L.P.,

          in its capacity as the Special Limited
Partner

	 By:    MPM Asset Management II LLC,
           Its General Partner

  

	 By:
	 	   /s/    MICHAEL STEINMETZ

	
	 Name: Michael Steinmetz

	 Title: Investment Manager

  

	 MPM BIOVENTURES II, L.P.

	 By:    MPM Asset Management II, L.P.,
           Its General Partner

	 By:    MPM Asset Management II LLC,
           Its General Partner

  

	 By:
	 	   /s/    MICHAEL STEINMETZ

	
	 Name: Michael Steinmetz

	 Title: Investment Manager

  

	 MPM BIOVENTURES II-QP, L.P.

	 By:    MPM Asset Management II, L.P.,
           Its General Partner

	 By:    MPM Asset Management II LLC,
           Its General Partner

  

	 By:
	 	   /s/    MICHAEL STEINMETZ

	
	 Name: Michael Steinmetz

	 Title: Investment Manager

  

	 Address:
	 	 One Cambridge Center

	 	 	 Cambridge, MA 02142

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

	VULCAN VENTURES, INC.
		
	By:	 	 /s/    WILLIAM D.
SAVOY       

	 Name:
	 	  
 William D. Savoy

	 Title:
	 	 President

	
	 Address:      505 Union Station
 505 Fifth Avenue South
 Suite
900
 Seattle, WA 98104
 Attn: Ruth Kunath

  
 [SIGNATURE
PAGE TO XCYTE THERAPIES, INC. 
 SERIES E STOCK AND WARRANT PURCHASE AGREEMENT] 

 EXHIBIT A 
  
 SCHEDULE OF INVESTORS 
  

	 Investor Name and Address

	  	 Number of
 Series E
 Preferred
Shares

	  	 Number
 of
 Warrant
 Shares

	  	 Amount of
 Investment
 for Series E
 Shares

	  	Purchase
Price for
Warrants

	 First Closing – November 13, 2001

	 ARCH VENTURE FUND III, L.P.
 1000 Second Avenue, Suite 3700
 Seattle, WA 98104-1053
 Attn: Bob Nelsen
	  	935,251	  	509,192	  	$	2,599,997.78	  	$	509.19
					
	 MPM BioVentures II-QP, LP
 One Cambridge Center
 Cambridge, MA 02142
 Attn: Julia Carpena
	  	484,316	  	263,683	  	$	1,346,398.48	  	$	263.68
					
	 MPM BioVentures GmbH & Co.
Parallel-Beteiligungs KG
 One Cambridge Center
 Cambridge, MA 02142
 Attn: Julia Carpena
	  	170,504	  	92,830	  	$	474,001.12	  	$	92.83
					
	 MPM BioVentures II, LP
 One Cambridge Center
 Cambridge, MA 02142
 Attn: Julia Carpena
	  	53,453	  	29,102	  	$	148,599.34	  	$	29.10
					
	 MPM Asset Management Investors 2000 B, LLC
 One Cambridge Center
 Cambridge, MA 02142
 Attn: Julia Carpena
	  	11,151	  	6,071	  	$	30,999.78	  	$	6.07
					
	 SPROUT CAPITAL VII, L.P.
 3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park, CA 94025
 Attn: Robert Curry
	  	312,914	  	170,364	  	$	869,900.92	  	$	170.36

	 Investor Name and Address

	  	 Number of
 Series E
 Preferred
Shares

	  	 Number
 of
 Warrant
 Shares

	  	 Amount of
 Investment
 for Series E
 Shares

	  	Purchase
Price for
Warrants

	 DLJ FIRST ESC L.P.
 3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park, CA 94025
 Attn: Robert Curry
	  	35,971	  	19,584	  	$	99,999.38	  	$	19.58
					
	 DLJ CAPITAL CORP.
 3000 Sand Hill Road
 Building Three, Suite 170
 Menlo Park, CA 94025
 Attn: Robert Curry
	  	7,194	  	3,917	  	$	19,999.32	  	$	3.92
					
	 ALTA CALIFORNIA PARTNERS, L.P.
 One Embarcadero Center, Suite 4050
 San Francisco, CA 94111
 Attn: Elaine Walker
	  	351,677	  	191,469	  	$	977,662.06	  	$	191.47
					
	 TGI FUND II, LC
 6501 Columbia Center
 701 - 5th Avenue
 Seattle, WA 98104
 Attn: Michael Beblo and Steven Johnson
	  	301,601	  	164,205	  	$	838,450.78	  	$	164.21
					
	 China Development Industrial Bank Inc.
 125, Nanking East Road, Section 5
 Taipei, Taiwan
 Attn: Mr. Tai-Ying Liu
Chairman & CEO
	  	1,078,925	  	587,415	  	$	2,999,411.50	  	$	587.41
					
	 CDIB Biotech USA Investment, Co., Ltd.
 PO Box 3444
 Road Town
 Tortola, British Virgin Islands
  
 Mailing Address:
 CDIB Biotech, Inc.
 21 N. Skokie Hwy., Suite 104
 Lake Bluff, IL 60044
 Attn: Bing Shen, Chairman
 Phone: (847) 283-9780
	  	287,714	  	156,644	  	$	799,844.92	  	$	156.64

  

 2 

	 Investor Name and Address

	  	 Number of
 Series E
 Preferred
Shares

	  	 Number
 of
 Warrant
 Shares

	  	 Amount of
 Investment
 for Series E
 Shares

	  	Purchase
Price for
Warrants

	 Second Closing – November 15, 2001

	 Vulcan Ventures, Inc.
 505 Union Station
 505 Fifth Avenue South, Suite 900
 Seattle, WA 98104
 Attn: Ruth Kunath
	  	719,424	  	391,686	  	$	1,999,998.72	  	$	391.69
	 	  	
	  	
	  	
	
	  	
	

	 TOTAL
	  	4,750,095	  	2,586,162	  	$	13,205,264.10	  	$	2,586.15
	 	  	
	  	
	  	
	
	  	
	

  

 3 

 EXHIBIT B 
  
 FORM OF AMENDED AND RESTATED 
 CERTIFICATE OF INCORPORATION 

 EXHIBIT C 
  
 SCHEDULE OF EXCEPTIONS 

 EXHIBIT D 
  
 FORM OF PROPRIETARY INFORMATION AGREEMENT 

 EXHIBIT E 
  
 FORM OF AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT 

 EXHIBIT F 
  
 FORM OF AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 EXHIBIT G 
  
 FORM OF OPINION OF COUNSEL TO THE COMPANY 

 EXHIBIT H 
  
 ADDITIONAL REPRESENTATIONS AND WARRANTIES 
 OF FOREIGN INVESTORS 
  
 China Development Industrial Bank Inc., CDIB Biotech USA Investment, Co., Ltd. and CDIB Biotech, Inc. (each a “Foreign Investor”), in addition to the other representations and warranties it has made in this Agreement, each
further represents and warrants to the Company that: 
  
 It is
familiar with Regulation S under the Securities Act and is not a “U.S. Person” as that term is defined in Regulation S and is not acquiring the Shares for the account or benefit of a U.S. Person, and it agrees not to make any disposition
of all or any portion of the Shares unless and until (A) such disposition is in accordance with Regulation S, and (B) (1) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such
disposition is made in accordance with such registration statement, or (2) the Foreign Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, and if requested by the Company, the Foreign Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration
under the Securities Act. 
  
 The acquisition by the Foreign
Investor of the Shares shall constitute a confirmation of the representations and warranties made by the Foreign Investor as of the Closing. The Foreign Investor further represents that it understands and agrees that, until registered under the
Securities Act or properly transferred pursuant to the provisions of Rule 144 as promulgated by the SEC, all certificates evidencing any of the Shares, whether upon initial issuance or upon any transfer thereof, shall bear a legend (in addition to
any legend required pursuant to the Investors’ Rights Agreement), prominently stamped or printed thereon, reading substantially as stated in Section 3.7(b).Series F Preferred Stock & Warrant Purchase Agreement

 Exhibit 10.3 
  
 XCYTE THERAPIES, INC. 
  
 SERIES F PREFERRED STOCK 
  
 AND WARRANT PURCHASE AGREEMENT 
  
 February 5, 2002 

 TABLE OF CONTENTS 
  

	 	 	 	  	 	  	Page

	 1.
	 	 Purchase and Sale of Stock
	  	1
	 	 	 1.1
	  	 Authorization, Sale and Issuance of Shares
	  	1
	 	 	 1.2
	  	 Closing
	  	1
	 	 	 1.3
	  	 Delivery
	  	2
	 	 	 1.4
	  	 Additional Closings
	  	2
			
	 2.
	 	 Representations and Warranties of the Company
	  	2
	 	 	 2.1
	  	 Organization, Good Standing and Qualification
	  	2
	 	 	 2.2
	  	 Authorization
	  	3
	 	 	 2.3
	  	 Capitalization
	  	3
	 	 	 2.4
	  	 Subsidiaries
	  	4
	 	 	 2.5
	  	 Governmental Consents
	  	4
	 	 	 2.6
	  	 Proprietary Information Agreement
	  	4
	 	 	 2.7
	  	 Patents and Trademarks
	  	4
	 	 	 2.8
	  	 Financial Statements
	  	5
	 	 	 2.9
	  	 Changes
	  	5
	 	 	 2.10
	  	 Liabilities
	  	6
	 	 	 2.11
	  	 Litigation
	  	6
	 	 	 2.12
	  	 Compliance with Other Instruments
	  	7
	 	 	 2.13
	  	 Offering
	  	7
	 	 	 2.14
	  	 Agreements; Action
	  	7
	 	 	 2.15
	  	 Labor Agreements and Actions
	  	8
	 	 	 2.16
	  	 Tax Returns, Payments and Elections
	  	8
	 	 	 2.17
	  	 Title to Property and Assets
	  	8
	 	 	 2.18
	  	 Registration Rights
	  	9
	 	 	 2.19
	  	 Employee Benefit Plans
	  	9
	 	 	 2.20
	  	 Obligations of Management
	  	9
	 	 	 2.21
	  	 Environmental and Safety Laws
	  	9
	 	 	 2.22
	  	 Disclosure
	  	9
	 	 	 2.23
	  	 Section 83(b) Elections
	  	9
	 	 	 2.24
	  	 Real Property Holding Corporation
	  	9
	 	 	 2.25
	  	 Insurance
	  	9
	 	 	 2.26
	  	 Investment Company Act
	  	9
			
	 3.
	 	 Representations and Warranties of the Investor
	  	9
	 	 	 3.1
	  	 Authorization
	  	10
	 	 	 3.2
	  	 Purchase Entirely for Own Account
	  	10
	 	 	 3.3
	  	 Disclosure of Information
	  	10
	 	 	 3.4
	  	 Investment Experience
	  	10
	 	 	 3.5
	  	 Regulation D
	  	10
	 	 	 3.6
	  	 Restricted Securities
	  	10

 TABLE OF CONTENTS 
 (cont’d.) 
  

	 	 	 	  	 	  	Page

	 	 	 3.7
	  	 Legends
	  	11
	 	 	 3.8
	  	 Regulation S
	  	11
			
	 4.
	 	 Conditions of Investor’s Obligations at Closing
	  	11
	 	 	 4.1
	  	 Representations and Warranties
	  	11
	 	 	 4.2
	  	 Performance
	  	11
	 	 	 4.3
	  	 Certificate
	  	12
	 	 	 4.4
	  	 Compliance Certificate
	  	12
	 	 	 4.5
	  	 Proceedings and Documents
	  	12
	 	 	 4.6
	  	 Board of Directors
	  	12
	 	 	 4.7
	  	 Rights Agreement
	  	12
	 	 	 4.8
	  	 Co-Sale Agreement
	  	12
	 	 	 4.9
	  	 Opinion of Company Counsel
	  	12
			
	 5.
	 	 Conditions of the Company’s Obligations at Closing
	  	12
	 	 	 5.1
	  	 Representations and Warranties
	  	12
	 	 	 5.2
	  	 Legal Matters
	  	12
			
	 6.
	 	 Miscellaneous
	  	13
	 	 	 6.1
	  	 Survival of Warranties
	  	13
	 	 	 6.2
	  	 Successors and Assigns
	  	13
	 	 	 6.3
	  	 Governing Law
	  	13
	 	 	 6.4
	  	 Counterparts
	  	13
	 	 	 6.5
	  	 Titles and Subtitles
	  	13
	 	 	 6.6
	  	 Notices
	  	13
	 	 	 6.7
	  	 Finder’s Fee
	  	13
	 	 	 6.8
	  	 Amendments and Waivers
	  	14
	 	 	 6.9
	  	 Severability
	  	14
	 	 	 6.10
	  	 Exculpation Among Investors
	  	14
	 	 	 6.11
	  	 Expenses
	  	14

  

 ii 

 EXHIBITS 
  

	A	Schedule of Investors 

	B	Form of Amended and Restated Certificate of Incorporation 

	C	Schedule of Exceptions 

	D	Form of Proprietary Information Agreement 

	E	Form of Amended and Restated Investor Rights Agreement 

	F	Form of Amended and Restated Right of First Refusal and Co-Sale Agreement 

	G	Form of Opinion of Counsel to the Company 

	H	Additional Representations and Warranties of Foreign Investors 

 XCYTE THERAPIES, INC. 
  
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 
  
 THIS SERIES F PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is made as of the fifth day
of February, 2002, by and between Xcyte Therapies, Inc., a Delaware corporation, located at 1124 Columbia Street, Suite 130, Seattle, WA 98104 (the “Company”), and the investors listed on Exhibit A hereto, each of which is
herein referred to as an “Investor.” 
  
 WHEREAS,
the Company desires to issue and sell up to 5,395,683 shares of Series F Preferred Stock and to issue warrants to purchase 2,937,650 shares of Common Stock to the Investors; and 
  
 WHEREAS, the Investors desire to purchase such shares and warrants from the Company on the terms and subject to the
conditions of this Agreement. 
  
 NOW THEREFORE, the parties
hereby agree as follows: 
  
 1. Purchase and Sale of
Stock. 
  
 1.1 Authorization, Sale and Issuance of
Shares 
  
 (a) The Company has authorized the sale and
issuance of up to 6,500,000 shares of Series F Preferred Stock (the “Series F Shares”) and the issuance of warrants to purchase 2,937,650 shares of Common Stock (the “Warrants” and together with the Series F Shares
the “Shares”). The Series F Shares have the rights, preferences, privileges and restrictions as set forth in the Company’s Restated Certificate of Incorporation in the form satisfactory to the Investors, a copy of which is
attached hereto as Exhibit B. The Common Stock issuable upon conversion of the Series F Shares is referred to hereinafter as the “Conversion Shares” and the Common Stock issuable upon exercise of the Warrants is referred to
hereinafter as the “Warrant Shares.” 
  
 (b)
Subject to the terms and conditions of this Agreement, the Company shall sell and issue to each Investor, and each Investor agrees, severally and not jointly, to purchase from the Company, that number of (i) Shares of Series F Preferred Stock at a
purchase price of $2.78 per share and (ii) Warrants at a cash purchase price of $0.001 per share of Common Stock set forth opposite each Investor’s name on Exhibit A attached hereto. Each Investor understands that the Shares and the
Warrants cannot be purchased separately and must be purchased in the proportion allocated on Exhibit A. 
  
 1.2 Closing. The purchase and sale of the Shares shall take place at the offices of Venture Law Group, 4750 Carillon Point, Kirkland, Washington,
at 10:00 a.m., on February 5, 2002, or at such other time and place as the Company and Investors may agree (which time and 

 
place are designated as the “Closing”). The date of such Closing is hereinafter referred to as the “Closing Date.”

  
 1.3 Delivery. At the Closing, the Company shall deliver
to each Investor a certificate representing the Shares which such Investor is purchasing against delivery to the Company by such Investor of a check, wire transfer of immediately available funds payable to the Company’s order or cancellation of
indebtedness (or any combination thereof) in the aggregate amount of the purchase price therefor. 
  
 1.4 Additional Closings. If the full number of Series F Shares of the Company is not sold at the Closing, the Company shall have the right, at any
time within thirty (30) days of the Closing Date (the “Subsequent Closing Date”), to sell the remaining authorized but unissued shares of Series F Shares and Warrants to purchase Common Stock to one or more additional purchasers as
determined by the Company, or to any Investor hereunder who wishes to acquire additional shares of Series F Shares and Warrants to purchase Common Stock at the price and on the terms set forth herein, provided that any such additional purchaser
shall be required to execute counterpart signature pages to this Agreement, the Investors’ Rights Agreement and the Co-Sale Agreement (each as defined in Section 2.2), and such additional purchasers will, upon delivery to the Company of such
signature pages and the purchase price, become parties to, and be bound by, such agreements, each to the same extent as if they had been Investors at the initial Closing. Immediately after each additional closing, Exhibit A to this Agreement
will be amended to list the additional purchasers purchasing shares of Series F Shares and Warrants to purchase Common Stock hereunder at each such additional closing. Any additional purchaser so acquiring shares of Series F Shares and Warrants to
purchase Common Stock shall be considered an “Investor” for the purposes of the Financing Documents (as defined below), and any Series F Shares so acquired by such additional purchaser shall be considered “Series F
Shares” and any Warrants to purchase Common Stock so acquired by such additional purchaser shall be considered “Warrants,” and together with the Series F Shares the “Shares”) for purposes of this Agreement
and all other agreements contemplated hereby. 
  
 2.
Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that, except as set forth on the Schedule of Exceptions attached hereto as Exhibit C, which exceptions shall be deemed to be
representations and warranties as if made hereunder: 
  
 2.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its
business as now conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business or
properties. As of the Closing, the Certificate shall be in the form attached hereto as Exhibit B and the Bylaws of the Company shall be in the form provided to counsel for the Investors prior to the Closing. 
  

 2 

 2.2 Authorization. 
  
 (a) The Company has all requisite corporate power and authority to execute and deliver, and to consummate the transactions
contemplated by this Agreement, the Amended and Restated Investor Rights Agreement attached as Exhibit E (“Rights Agreement”) and the Amended and Restated Right of First Refusal and Co-Sale Agreement attached as Exhibit
F (the “Co-Sale Agreement” with the Agreement and Rights Agreement, the “Financing Documents”). All corporate action on the part of the Company, its officers, directors and stockholders necessary for the
execution and delivery of, and the consummation of the transactions contemplated by the Financing Documents, the performance of all obligations of the Company under the Financing Documents and the authorization, sale, issuance (or reservation for
issuance) and delivery of the Shares being sold hereunder and the Conversion Shares and Warrant Shares has been taken or will be taken prior to the Closing. The Financing Documents, upon execution and delivery by the Company and assuming the due and
proper execution and delivery by the other parties, constitute valid and binding obligations of the Company enforceable in accordance with their respective terms, except as such enforcement may be limited by bankruptcy, insolvency, moratorium and
other laws of general application affecting the enforcement of creditors’ rights. 
  
 (b) The Shares, when issued in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable and will be free of any liens or encumbrances known to, or caused or created by,
the Company; provided, however, that the Shares may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein, as may be required by changes in such laws and as contemplated by the Financing
Documents. Upon conversion of the Series F Shares into the Conversion Shares and Warrants into Warrant Shares in conformity with the Certificate, such Conversion Shares and Warrant Shares will be duly authorized, validly issued, fully paid and
nonassessable, and will be free of any liens or encumbrances caused or created by the Company; provided, however, that the Conversion Shares and Warrant Shares may be subject to restrictions on transfer under state and/or federal
securities laws as set forth herein, as may be required by changes in such law and as contemplated by the Financing Documents. 
  
 (c) Except as set forth herein or in the Financing Documents, no entity has any right of first refusal or any preemptive rights in connection with the
issuance of the Shares, the Warrant Shares, the Conversion Shares or any future issuances of securities by the Company. 
  
 2.3 Capitalization. 
  
 (a) As of Closing, the authorized capital of the Company shall consist of: (i) 70,000,000 shares of Common Stock, and (ii), 42,000,000 shares of
Preferred Stock (the “Preferred Stock”), of which 7,300,080 have been designated Series A Preferred Stock, 4,097,580 have been designated Series B Preferred Stock, 7,212,316 have been designated Series C Preferred Stock, 10,300,000
have been designated Series D Preferred Stock, 6,500,000 have been designated Series E Preferred Stock and 6,500,000 have been designated Series F Preferred 

  

 3 

 
Stock. As of the Closing, 7,437,380 shares of Common Stock, warrants to purchase 3,083,110 shares of Common Stock, 6,860,512 shares of Series A Preferred
Stock, warrants to purchase 439,568 shares of Series A Preferred Stock, 3,903,080 shares of Series B Preferred Stock, warrants to purchase 194,500 shares of Series B Preferred Stock, 7,185,630 shares of Series C Preferred Stock, and warrants to
purchase 26,686 shares of Series C Preferred Stock, 10,109,825 shares of Series D Preferred Stock, warrants to purchase 103,741 shares of Series D Preferred Stock, 4,750,095 shares of Series E Preferred Stock, warrants to purchase 10,000 shares of
Series E Preferred Stock and no shares of Series F Preferred Stock will be outstanding. 
  
 (b) Except as set forth in this Agreement and the exhibits thereto, there are no outstanding options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the
Company of any shares of its capital stock except that the Company has reserved (i) the Shares for issuance at each Closing, (ii) the Common Stock issuable upon conversion of the Preferred Stock, (iii) 4,400,000 shares of Common Stock reserved for
issuance pursuant to stock option plans adopted by the Company of which 2,944,354 options have been granted and remain outstanding, with 680,414 shares remaining for grant as of the Closing. 
  
 2.4 Subsidiaries. The Company does not presently own or control,
directly or indirectly, any interest in any other corporation, association, or other business entity. 
  
 2.5 Governmental Consents. 
  
 (a) No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local
governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by the Financing Documents. 
  

(b) No consent, approval, waiver or other action by any person under any contract, agreement, indenture, lease, instrument or other document to which
the Company is a party or bound is required or necessary for the execution, delivery and performance of, or the consummation of the transactions contemplated by, any of the Financing Documents by the Company. 
  
 2.6 Proprietary Information. Each former and present employee,
consultant and officer of the Company has executed and each future employee, consultant and officer will execute, a Proprietary Information Agreement in the form attached hereto as Exhibit D and no exceptions have been taken by any such
employee, consultant or officer to the terms of such agreement. The Company, after reasonable investigation, is not aware that any of its employees, officers or consultants are in violation thereof, and the Company will use its best efforts to
prevent any such violation. 
  
 2.7 Patents and Trademarks.
The Company has sufficient title and ownership of all patents, trademarks, service marks, trade names, copyrights, trade secrets, information, proprietary rights and processes necessary for its business as now conducted and as proposed to 

  

 4 

 
be conducted without any conflict with or infringement of the rights of others. There are no outstanding options, licenses, or agreements of any kind
relating to the foregoing, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary
rights and processes of any other person or entity. The Company has not received any communications alleging that the Company has violated or, by conducting its business as proposed, would violate any of the patents, trademarks, service marks, trade
names, copyrights or trade secrets or other proprietary rights of any other person or entity. The Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other
agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of the Company or that would conflict with the Company’s
business as proposed to be conducted. Neither the execution nor delivery of this Agreement, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as proposed, will, to the
best of the Company’s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such employees is now obligated. The Company
does not believe it is or will be necessary to utilize any inventions of any of its employees (or people it currently intends to hire) made prior to their employment by the Company. 
  
 2.8 Financial Statements. The Company has delivered to each Investor (i) its unaudited balance sheet as of December
31, 2001 and unaudited statement of income for the period from January 1, 2001 to December 31, 2001 and audited financial statements as of December 31, 2000 (collectively the “Financial Statements”). The Financial Statements,
together with the notes thereto, are complete and correct in all material respects and have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods indicated, except as disclosed
therein, and present fairly the financial condition and position of the Company as of December 31, 2001; provided, however, that the unaudited financial statements are subject to normal recurring year-end audit adjustments (which are not expected to
be material), and do not contain all footnotes required under generally accepted accounting principles. 
  
 2.9 Changes. Since December 31, 2001, there has not been: 
  

(a) Any change in the assets, liabilities, financial condition or operations of the Company from that reflected in the Financial Statements, other
than changes in the ordinary course of business, or any other event or condition of any character, any of which individually or in the aggregate has had or is expected to have a material adverse effect on such assets, liabilities, financial
condition or operations of the Company; 
  
 (b) Any resignation
or termination of any key officers of the Company; and the Company, to the best of its knowledge, does not know of the impending resignation or termination of employment of any such officer; 
  

 5 

 (c) Any material change, except in the ordinary course of business, in the contingent obligations of the
Company by way of guaranty, endorsement, indemnity, warranty or otherwise; 
  
 (d) Any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting the properties, business or prospects or financial condition of the Company; 
  
 (e) Any direct or indirect loans made by the Company to, or any material
change in, any compensation arrangement or agreement with, any stockholder, employee, officer or director of the Company, other than advances made in the ordinary course of business; 
  
 (f) Any declaration or payment of any dividend or other distribution of the assets of the Company; 
  
 (g) Any debt, obligation or liability incurred, assumed or guaranteed by the
Company, except those for immaterial amounts and for current liabilities incurred in the ordinary course of business; or any waiver by the Company of a valuable right or of a material debt owed to it; 
  
 (h) Any sale, assignment or transfer of any patents, trademarks, copyrights,
trade secrets or other intangible assets; and 
  
 (i) To the
Company’s knowledge, any change in any material agreement to which the Company is a party or by which it is bound which materially and adversely affects the business, assets, liabilities, financial condition, operations or prospects of the
Company, including compensation agreements with the Company’s employees. 
  
 2.10 Liabilities. The Company has no material liabilities and knows of no material contingent liabilities not disclosed in the Financial Statements, except current liabilities incurred in the ordinary course of
business subsequent to December 31, 2001, which have not been, either in any individual case or in the aggregate, materially adverse. 
  
 2.11 Litigation. There is no action, suit, proceeding or investigation pending or currently threatened against the Company that questions the
validity of this Agreement or the right of the Company to enter into it, or to consummate the transactions contemplated hereby, or which might result, either individually or in the aggregate, in any material adverse changes in the assets, condition,
affairs or prospects of the Company, financially or otherwise, or any change in the current equity ownership of the Company, nor is the Company aware that there is any basis for the foregoing. The foregoing includes, without limitation, actions
pending or threatened (or any basis therefor known to the Company) involving the prior employment of any of the Company’s employees, their use in connection with the Company’s business of any information or techniques allegedly proprietary
to any of their former employers, or their obligations under any agreements with prior employers. The Company is not a party or subject to the provisions of 
  

 6 

 any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action,
suit, proceeding or investigation by the Company currently pending or which the Company intends to initiate. 
  
 2.12 Compliance with Other Instruments. The Company is not in violation or default of any provision of its Certificate or Bylaws or any provision
of any mortgage, indenture, contract, agreement, instrument, judgment, order, writ, or decree to which it is a party or by which it is bound or, to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the
Company which would materially and adversely affect the business, assets, liabilities, financial condition, operations or prospects of the Company. The execution, delivery and performance of this Agreement, the Rights Agreement and the Co-Sale
Agreement and the consummation of the transactions contemplated hereby and thereby will not result in any such material violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under
any such provision, instrument, judgment, order, writ, decree or contract or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company. 
  
 2.13 Offering. Subject in part to the accuracy of the Investors’ representations set forth in Section 3 hereof,
the offer, sale and issuance of the Shares as contemplated by this Agreement and the issuance of the Conversion Shares or Warrant Shares upon the conversion of such Shares are exempt from the registration requirements of the Securities Act of 1933,
as amended (the “Securities Act”), and the registration, qualification or compliance requirements of any applicable blue sky or other state securities laws, and neither the Company nor any authorized agent acting on its behalf will
take any action that would cause the loss of any such exemption. 
  
 2.14 Agreements; Action. 
  
 (a) There are no
agreements, understandings or proposed transactions between the Company and any of its officers, directors, affiliates, or any affiliate thereof. 
  
 (b) There are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound
which involve (i) obligations of, or payments to the Company in excess of $25,000, or (ii) the license of any patent, copyright, trade secret or other proprietary right to or from the Company (other than licenses arising from the purchase of
“off-the-shelf” products) or (iii) obligations of, or payments by, the Company to any officer, director, employee or family member of any such individual. 
  
 (c) The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to
any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $25,000 or in excess of $75,000 in the aggregate, (iii) made any loans or advances to any person,
other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than in the ordinary course of business. 
  

 7 

 (d) The Company is not a party to and is not bound by any contract, agreement or instrument, or subject
to any restriction under its Certificate or Bylaws, which materially adversely affects its business as now conducted and as proposed to be conducted. 
  
 (e) The Company has not engaged in the past twelve (12) months in any discussion (i) with any representative of any corporation or corporations regarding
the consolidation or merger of the Company with or into any such corporation or corporations, (ii) with any corporation, partnership, association or other business entity or any individual regarding the sale, conveyance or disposition of all or
substantially all of the assets of the Company, or (iii) regarding any other form of liquidation, dissolution or winding up of the Company. 
  
 2.15 Labor Agreements and Actions. The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any
written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the knowledge of the Company, has sought to represent any of the employees, representatives or agents of the
Company. There is no strike or other labor dispute involving the Company pending, or to the knowledge of the Company threatened, which could have a material adverse effect on the assets, properties, financial condition, operating results, or
business of the Company (as such business is presently conducted and as it is proposed to be conducted), nor is the Company aware of any labor organization activity involving its employees. To the best of its knowledge, the Company is not aware that
any officer or key employee, or that any group of key employees, intends to terminate their employment with the Company, nor does the Company have a present intention to terminate the employment of any of the foregoing. The employment of each
officer and employee of the Company is terminable at the will of the Company. 
  
 2.16 Tax Returns, Payments and Elections. The Company has filed all tax returns and reports as required by law. These returns and reports are true and correct in all material respects. The Company has paid all
taxes and other assessments due, except those contested by it in good faith which are listed in the Schedule of Exceptions, attached hereto as Exhibit C. The provision for taxes of the Company as shown in the Balance Sheet is adequate for
taxes due or accrued as of the date thereof. The Company has not elected pursuant to the Internal Revenue Code of 1986, as amended (the “Code”), to be treated as a Subchapter S corporation or a collapsible corporation pursuant to
Section 1362(a) or Section 341(f) of the Code, respectively, nor has it made any other elections pursuant to the Code (other than elections which relate solely to methods of accounting, depreciation or amortization) which would have a material
effect on the Company, its financial condition, its business as presently conducted or proposed to be conducted or any of its properties or material assets. 
  
 2.17 Title to Property and Assets. The Company owns its property and assets free and clear of all mortgages, liens, loans and encumbrances, except
such encumbrances and liens which arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in compliance
with such leases and, to the best of its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances. 
  

 8 

 2.18 Registration Rights. Except as provided in the Rights Agreement, a form of which is attached
hereto as Exhibit E, the Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity. 
  
 2.19 Employee Benefit Plans. The Company does not have any Employee Benefit Plan as defined in the Employee Retirement Income Security Act of 1974,
as amended. 
  
 2.20 Obligations of Management. Each
officer of the Company is currently devoting his or her full-time to the conduct of the business of the Company. The Company is not aware of any officer or key employee or the Company planning to work less than full-time at the Company in the
future. 
  
 2.21 Environmental and Safety Laws. To the best
of its knowledge, the Company is not in violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply
with any such existing statute, law or regulation. 
  
 2.22
Disclosure. The Company has fully provided each Investor with all the information which such Investor has requested for deciding whether to purchase the Shares and all information which the Company believes is reasonably necessary to enable
such Investor to make such decision. To the best of the Company’s knowledge, neither this Agreement, the Rights Agreement, the Co-Sale Agreement nor any other statements or certificates made or delivered in connection herewith, when taken as a
whole, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading. 
  
 2.23 Section 83(b) Elections.2.23. To the Company’s knowledge, all elections and notices permitted by Section 83(b) of the Internal Revenue
Code and analogous provisions of applicable state tax laws have been timely filed by all employees who have purchased shares of the Company’s common stock under agreements that provide for the vesting of such shares. 
  
 2.24 Real Property Holding Corporation. The Company is not a real
property holding corporation within the meaning of Internal Revenue Code Section 897(c)(2) and any regulations promulgated thereunder. 
  
 2.25 Insurance. The Company has fire and casualty insurance policies with coverage customary for companies similarly situated to the Company.

  
 2.26 Investment Company Act. The Company is not an
“investment company”, or a company “controlled” by an “investment”, within the meaning of the Investment Company Act of 1940, as amended. 
  
 3. Representations and Warranties of the Investor. Each Investor hereby severally and not jointly represents and
warrants that: 
  

 9 

 3.1 Authorization. This Agreement when executed and delivered by such Investor shall constitute a
valid and legally binding obligation, enforceable in accordance with its terms, subject to the effect of applicable bankruptcy, insolvency, reorganization, moratorium or other similar federal or state laws affecting the rights of creditors and the
effect of rules of law governing specific performance, injunctive relief or other equitable remedies. 
  
 3.2 Purchase Entirely for Own Account. This Agreement is made with each Investor in reliance upon such Investor’s representations and
warranties to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Shares to be received by such Investor, the Warrant Shares and the Conversion Shares (collectively, the
“Securities”) will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, each Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any person or entity
to sell, transfer or grant participation to such person or to any third person, with respect to any of the Securities. Each Investor represents that it has full power and authority to enter into this Agreement. 
  
 3.3 Disclosure of Information. Each Investor believes it has received
all the information it considers necessary or appropriate for deciding whether to purchase the Shares. Each Investor further represents that it has had an opportunity to ask questions, if any, and receive answers from the Company regarding the terms
and conditions of the offering of the Shares. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Investors to rely thereon. 
  
 3.4 Investment Experience. Each Investor is an investor in securities
of companies in the development stage and acknowledges that it is able to fend for itself, and bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the
merits and risks of the investment in the Shares. If other than an individual, Investor also represents it has not been organized for the purpose of acquiring the Shares. 
  
 3.5 Regulation D. Each Investor is an “Accredited Investor” as that term is defined in Regulation D
promulgated under the Securities Act. 
  
 3.6 Restricted
Securities. Each Investor understands that the Shares it is purchasing (and the Conversion Shares) are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a
transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. In this connection, each Investor
represents that it is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. Each Investor acknowledges that the Company filed a registration statement for a public
offering of its common stock, which was withdrawn effective December 3, 2001. Each Investor 

  

 10 

 
understands that this offering is not intended to be part of the public offering, and that the Investor will not be able to rely on the protection of Section
11 of the Securities Act. 
  
 3.7 Legends. It is understood
that the certificates evidencing the Series F Preferred Stock (or the Conversion Shares) and the Warrants (or the Warrant Shares) may bear one or all of the following legends: 
  
 (a) “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).
THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT. THESE SECURITIES ARE SUBJECT TO A CERTAIN VOTING PROVISION ENTERED INTO BY AND AMONG THE INVESTORS.” 
  
 (b) “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR
APPLICABLE SECURITIES LAWS. THESE SECURITIES MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OTHER THAN IN COMPLIANCE WITH REGULATION S OF THE ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER
THE ACT AND APPLICABLE STATE SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE ACT AND APPLICABLE STATE SECURITIES LAWS.” 
  
 (c) Any other legends required by the laws of the State of Delaware or any other applicable blue sky or state securities
laws. 
  
 3.8 Regulation S. V-Sciences Investments Pte Ltd
hereby makes the additional representations and warranties set forth in Exhibit H. 
  
 4. Conditions of Investor’s Obligations at Closing. The obligations of each Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, any of
which may be waived in whole or in part by such Investor with respect to himself, herself or itself unless required by state or federal law: 
  
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing
Date with the same effect as though such representations and warranties had been made on and as of the date of the Closing. 
  
 4.2 Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the Closing. 
  

 11 

 4.3 Certificate. The Certificate shall have been filed with the Secretary of State of the State of
Delaware. 
  
 4.4 Compliance Certificate. The President of
the Company shall deliver to counsel for the Investors at the Closing a certificate certifying that the conditions specified in Sections 4.1, 4.2 and 4.3 have been fulfilled and stating that there shall have been no adverse change in the business,
affairs, prospects, operations, properties, assets, liabilities or condition of the Company since the date of this Agreement. 
  
 4.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all
documents incident thereto shall be reasonably satisfactory in form and substance to each Investor and counsel to any of the Investors, and they shall have received all such counterpart original and certified or other copies of such documents as
they may reasonably request. 
  
 4.6 Board of Directors. As
of the Closing, the Board of Directors will be comprised of seven members: Ronald J. Berenson, Craig Parker, Jean Deleage, Peter Langecker, Robert Nelsen, Michael Steinmetz and Robert Williams. 
  
 4.7 Rights Agreement. The Company and the Investors shall have entered
into the Rights Agreement in the form attached hereto as Exhibit E. 
  
 4.8 Co-Sale Agreement. The Company, certain stockholders and certain of the Investors shall have entered into the Co-Sale Agreement in the form attached hereto as Exhibit F. 
  
 4.9 Opinion of Company Counsel. The Investors shall have received from
Venture Law Group, counsel to the Company, an opinion addressed to them, dated the Closing Date, in the form attached hereto as Exhibit G. 
  
 5. Conditions of the Company’s Obligations at Closing. The obligations of the Company to each Investor under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions any of which may be waived in whole or in part by the Company unless required by state or federal law: 
  
 5.1 Representations and Warranties. The representations and warranties of each Investor contained in Section 3 hereof
shall be true and correct on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of that date; and each Investor shall have performed all obligations and conditions required to be
performed or observed by he, she or it on or prior to the Closing Date. 
  
 5.2 Legal Matters. All material matters of a legal nature which pertain to this agreement and the transactions contemplated hereby, shall have been reasonably approved by counsel to the Company. 
  

 12 

 6. Miscellaneous. 
  
 6.1 Survival of Warranties. The warranties, representations and covenants of the Company and Investors contained in
or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company.

  
 6.2 Successors and Assigns. The terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  
 6.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Washington.

  
 6.4 Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement. 
  
 6.6 Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal deliver to the party to be notified, the refusal of delivery by such person, or five (5) days
after deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party in Exhibit A attached hereto or in the case of the Company on
the first page of this Agreement, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties. 
  
 6.7 Finder’s Fee. Each party represents that it neither is nor will be obligated for any finders’ fee or commission in connection with
this transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or
asserted liability) for which the Investor or any of its officers, partners, employees, or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the
nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
  

 13 

 6.8 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any
term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Series F Shares. Any amendment or waiver
effected in accordance with this Section 6.8 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities are convertible), each future holder of all such
securities, and the Company; provided, however, that no condition set forth in Section 4 hereof may be waived with respect to any Investor who does not consent thereto. 
  
 6.9 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such
provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  
 6.10 Exculpation Among Investors. Each Investor acknowledges that it
is not relying upon any person, firm or corporation, other than the Company and its officers and directors, in making its investment decision to invest in the Company. Each Investor agrees that no other Investor nor the respective controlling
persons, officers, directors, partners, agents or employees of any such other Investor shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with each Investor’s purchase of the Shares,
Conversion Shares and Warrant Shares. 
  
 6.11 Expenses.
Upon the Closing of the purchase and sale of securities as contemplated by this Agreement and the exhibits thereto, the Company shall pay the fees and reasonable expenses of counsel for the Investors, which fees shall not exceed $10,000.00.

  
 (signature page follows) 
  

 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

	XCYTE THERAPIES, INC.
		
	 By:
	 	 /s/    Ronald J. Berenson        

		
	 Name:
	 	 Ron Berenson

	(print)
		
	 Title:
	 	 President & CEO

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	CALPERS HEALTHCARE SIDE FUND, L.P.
	 By: ARCH Venture Partners V, L.P.,

	 its general partner

	 By: ARCH Venture Partners V, LLC,

	 its general partner

		
	 By:
	 	 /s/    ROBERT T.
NELSON        

		
	 Name:
	 	 Robert T. Nelson

		
	 Title:
	 	 Its Managing Director

	
	 Address: c/o ARCH Venture Partners V, L.P.

	 8725 W. Higgins Road, Suite 290

	 Chicago, IL 60631

	 Attn: Mark McDonnell

	
	 Phone Number: (773) 380-6600

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	 VECTOR LATER-STAGE EQUITY FUND II
 (QP), L.P.

	 By:
	 	 VECTOR FUND MANAGEMENT II, L.L.C.

	 	 	 Its:General Partner

		
	 By:
	 	 /s/    DOUGLAS
REED        

	 	 	 Douglas Reed, M.D.

		
	 Its:
	 	 Managing Director

	
	 Address: 1751 Lake Cook Road, Suite 350
                 Deerfield, IL
60015

	
	 Phone Number:  (847) 374-3946

  

	 VECTOR LATER-STAGE EQUITY FUND II,
 L.P.

	 By:
	 	 VECTOR FUND MANAGEMENT II, L.L.C.

	 	 	 Its:General Partner

		
	 By:
	 	 /s/    DOUGLAS
REED        

	 	 	 Douglas Reed, M.D.

		
	 Its:
	 	 Managing Director

	
	 Address: 1751 Lake Cook Road, Suite 350
                 Deerfield, IL
60015

	
	 Phone Number:  (847) 374-3946

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	PALIVACINNI PARTNERS, LLC
		
	 By:
	 	 /S/    DOUGLAS REED        

	 	 	   Douglas Reed, M.D.

	 	 	   Managing Member

	
	 Address: c/o Vector Fund Management, L.P.

	 	 	        1751 Lake Cook Road, Suite 350

	 	 	        Deerfield, IL 60015

	
	 Phone Number: (847) 374-3946

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	RIVERVEST VENTURE FUND I, L.P.
	 By: Its general partner, RiverVest Venture
 Partners I, LLC

		
	 By:
	 	 /S/    MARK
MENDEL        

	
	 Name: Mark Mendel

	
	 Title: Managing Member

	
	 Address: 7733 Forsyth Boulevard, Suite 1650
                 St. Louis, MO
63105

	
	 Phone Number: (314) 726-6739

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	EDWARD F. BRENNAN
	
	 /s/    EDWARD F.
BRENNAN        

	 Address: 1216 Arguello Blvd.
                 San Francisco, CA
94122-2707

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	1998 CO-INVESTING LLC
		
	 By:
	 	 /s/    JEFFREY
MCDONNELL        

		
	 Name:
	 	 Jeffrey McDonnell

		
	 Title:
	 	 Manager

	
	 Address:   c/o J&J Management Services
 1034 S. Brentwood Boulevard, Suite 1860
 St. Louis, MO 63117-1218
 Attn: Jeffrey M. McDonnell

	
	 Phone Number: (314) 862-1040

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	SPROUT CEO FUND, L.P.
		
	 By:
	 	 /s/    CRAIG C.
PARKER        

		
	 Name:
	 	 Craig C. Parker

		
	 Title:
	 	 Partner

	
	 Address:   c/o Sprout Group
 277 Park Avenue, 42nd Floor
 New York, NY 10172
 Attn: Craig C. Parker

	
	 Phone Number:    650-234-2728

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	ALTA EMBARCADERO PARTNERS, LLC
	By: Alta California Management Partners, L.P.
		
	 By:
	 	 /s/    JEAN
DELEAGE        

	                     Member

	 Name:
	 	  

	 Address:   One Embarcadero Center, Suite 4050
 San Francisco, CA 94111
 Attn: Elaine
Walker

	
	 Phone Number: (415) 362-4022

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	TOM ALBERG
	
	 /s/    TOM
ALBERG      

	 Address:
	 	 c/o Madrona Investment Group
 1000 - 2nd Avenue
 Seattle, WA 98104

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

	V–Sciences Investments Pte Ltd
		
	 By:
	 	 /s/    S
Iswaran        

		
	 Name:
	 	 Mr S Iswaran

		
	 Title:
	 	 Director

	
	 Address:   8 Shenton Way
 # 38-03 Temasek
Tower
 Singapore 06881

	
	 Fax Number:    (65) 324-4991

  
 SIGNATURE PAGE
TO XCYTE THERAPIES, INC. 
 SERIES F STOCK AND WARRANT PURCHASE AGREEMENT 

 EXHIBIT A 
  
 SCHEDULE OF INVESTORS 
  
 First Closing: February 5, 2002 
  

	 Investor Name and Address

	  	 Number of
 Series F
Preferred
 Shares

	  	 Number of
 Warrant
 Shares

	  	 Amount of
Investment for
Series F
 Shares

	  	Purchase
Price for
Warrants

	 RiverVest Venture Fund I, L.P.
 7733 Forsyth Boulevard, Suite 1650
 St. Louis, MO 63105
	  	1,078,925	  	587,415	  	$	2,999,411.50	  	$	587.42
					
	 CalPERS Healthcare Side Fund, L.P.
 c/o ARCH Venture Partners V, L.P.
 8725 W. Higgins Road, Suite 290
 Chicago, IL 60631
 Attn: Mark McDonnell
	  	899,104	  	489,512	  	$	2,499,509.12	  	$	489.51
					
	 Vector Later-Stage Equity Fund II (QP), L.P.
 1751 Lake Cook Road, Suite 350
 Deerfield, IL 60015
	  	809,194	  	440,561	  	$	2,249,559.32	  	$	440.56
					
	 Vector Later-Stage Equity Fund II, L.P.
 1751 Lake Cook Road, Suite 350
 Deerfield, IL 60015
	  	269,731	  	146,854	  	$	749,852.18	  	$	146.85
					
	 1998 Co-Investing LLC
 c/o J&J Management Services
 1034 S. Brentwood Blvd., Suite 1860
 St. Louis, MO 63117-1218
 Attn: Jeffrey M. McDonnell
	  	179,820	  	97,902	  	$	499,899.60	  	$	97.90
					
	 Tom Alberg
 c/o Madrona Investment Group
 1000 - 2nd Avenue
 Seattle, WA 98104
	  	71,928	  	39,161	  	$	199,959.84	  	$	39.16
					
	 Palivacinni Partners, LLC
 1751 Lake Cook Road, Suite 350
 Deerfield, IL 60015
 Attn: Douglas Reed, Managing Member
	  	35,964	  	19,580	  	$	99,979.92	  	$	19.58

	 Investor Name and Address

	  	 Number of
 Series F
Preferred
 Shares

	  	 Number of
 Warrant
 Shares

	  	 Amount of
Investment for
Series F
 Shares

	  	Purchase
Price for
Warrants

	 Edward F. Brennan
 1216 Arguello Blvd.
 San Francisco, CA 94122-2707
	  	8,991	  	4,895	  	$	24,994.98	  	$	4.90
					
	 Alta Embarcadero Partners, LLC
 One Embarcadero Center, Suite 4050
 San Francisco, CA 94111
 Attn: Elaine Walker
	  	8,035	  	4,375	  	$	22,337.30	  	$	4.38
					
	 Sprout CEO Fund, L.P.
 c/o Sprout Group
 277 Park Avenue, 42nd Floor
 New York, NY 10172
 Attn: Craig C. Parker
	  	3,634	  	1,979	  	$	10,102.52	  	$	1.98
					
	 FIRST CLOSING TOTAL:
	  	3,365,326	  	1,832,234	  	$	9,355,606.28	  	$	1,832.24

  
 Second Closing:
March 6, 2002 
  

	 Investor Name and Address

	  	 Number of
 Series F
Preferred
 Shares

	  	 Number of
 Warrant
 Shares

	  	 Amount of
Investment for
Series F
 Shares

	  	Purchase
Price for
Warrants

	 V-Sciences Investments Pte Ltd
 8 Shenton Way
 #38-03 Temasek Tower
 Singapore 068811
 Attn: Mr. S. Iswaran
	  	1,078,925	  	587,415	  	$	2,999,411.50	  	$	587.42
					
	 SECOND CLOSING TOTAL:
	  	1,078,925	  	587,415	  	$	2,999,411.50	  	$	587.42
	 AGGREGATE TOTAL:
	  	4,444,251	  	2,419,649	  	$	12,355,017.78	  	$	2,419.66

  

 2 

 EXHIBIT B 
  
 FORM OF AMENDED AND RESTATED 
 CERTIFICATE OF INCORPORATION 

 EXHIBIT C 
  
 SCHEDULE OF EXCEPTIONS 

 EXHIBIT D 
  
 FORM OF PROPRIETARY INFORMATION AGREEMENT 
  

 EXHIBIT E 
  
 FORM OF AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT 

 EXHIBIT F 
  
 FORM OF AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 EXHIBIT G 
  
 FORM OF OPINION OF COUNSEL TO THE COMPANY 

 EXHIBIT H 
  
 ADDITIONAL REPRESENTATIONS AND WARRANTIES 
 OF FOREIGN INVESTORS 
  
 V-Sciences Investments Pte Ltd (each a “Foreign Investor”), in addition to the other representations and warranties it has made in this Agreement, each further represents and warrants to the Company that: 
  
 It is familiar with Regulation S under the Securities Act and is not a
“U.S. Person” as that term is defined in Regulation S and is not acquiring the Shares for the account or benefit of a U.S. Person, and it agrees not to make any disposition of all or any portion of the Shares unless and until (A) such
disposition is in accordance with Regulation S, and (B) (1) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement, or
(2) the Foreign Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if requested by the Company, the
Foreign Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration under the Securities Act. 
  
 The acquisition by the Foreign Investor of the Shares shall constitute a
confirmation of the representations and warranties made by the Foreign Investor as of the Closing. The Foreign Investor further represents that it understands and agrees that, until registered under the Securities Act or properly transferred
pursuant to the provisions of Rule 144 as promulgated by the SEC, all certificates evidencing any of the Shares, whether upon initial issuance or upon any transfer thereof, shall bear a legend (in addition to any legend required pursuant to the
Investors’ Rights Agreement), prominently stamped or printed thereon, reading substantially as stated in Section 3.7(b).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]